Hailed as potential game-changers, new Alzheimer's drugs costing up to £90,000 per patient are facing severe scrutiny. A comprehensive major review has concluded that these expensive treatments offer marginal improvements so negligible they are effectively invisible to those suffering from the devastating condition.

The findings have ignited a fierce backlash, challenging the narrative that these pharmaceutical breakthroughs provide meaningful relief. Critics argue that despite the hefty price tag, the medicines fail to deliver the tangible health advancements patients and families desperately need, raising difficult questions about their value in current healthcare strategies.